The downgrade from Overweight to Neutral by a prominent analyst suggests a less optimistic outlook on Axonics' stock performance. The reduction in the price target further implies that the expected future price is now lower than previously estimated, which could lead to a negative short-term impact on the stock price as investors adjust their expectations.